相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary
Julie R. Brahmer et al.
JOURNAL OF ONCOLOGY PRACTICE (2018)
A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator's choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141
Naomi Kiyota et al.
ORAL ONCOLOGY (2017)
Resistance to PD1/PDL1 checkpoint inhibition
Jake S. O'Donnell et al.
CANCER TREATMENT REVIEWS (2017)
A model-based exposure-response (E-R) assessment of a nivolumab (NIVO) 4-weekly (Q4W) dosing schedule across multiple tumor types
Xiaochen Zhao et al.
CANCER RESEARCH (2017)
Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic
S. P. Kang et al.
ANNALS OF ONCOLOGY (2017)
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Padmanee Sharma et al.
CELL (2017)
Immune based therapy for melanoma
Robert Ancuceanu et al.
INDIAN JOURNAL OF MEDICAL RESEARCH (2016)
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
Antoni Ribas et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Acquired resistance to immunotherapy and future challenges
Nicholas P. Restifo et al.
NATURE REVIEWS CANCER (2016)
Emerging immune checkpoints for cancer therapy
Xiaodong Li et al.
ACTA ONCOLOGICA (2015)
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Suzanne L. Topalian et al.
CANCER CELL (2015)
Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
Amita Patnaik et al.
CLINICAL CANCER RESEARCH (2015)
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
Dirk Schadendorf et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Matias E. Valsecchi
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Neoantigens in cancer immunotherapy
Ton N. Schumacher et al.
SCIENCE (2015)
CATECHOLAMINES INCREASE IN VITRO PROLIFERATION OF MURINE B16F10 MELANOMA CELLS
C. Caruntu et al.
ACTA ENDOCRINOLOGICA-BUCHAREST (2014)
A PHASE 3 RANDOMIZED, OPEN-LABEL STUDY OF NIVOLUMAB (ANTI-PD-1; BMS-936558; ONO-4538) VERSUS INVESTIGATOR'S CHOICE CHEMOTHERAPY (ICC) IN PATIENTS WITH ADVANCED MELANOMA AFTER PRIOR ANTI-CTLA-4 THERAPY
J. S. Weber et al.
ANNALS OF ONCOLOGY (2014)
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
Suzanne L. Topalian et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
Caroline Robert et al.
LANCET (2014)
Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials
J. D. Wolchok et al.
ANNALS OF ONCOLOGY (2013)
Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma
Antoni Ribas et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Adoptive Cell Transfer for Patients With Metastatic Melanoma: The Potential and Promise of Cancer Immunotherapy
Giao Q. Phan et al.
CANCER CONTROL (2013)
Immune Parameters in The Prognosis and Therapy Monitoring of Cutaneous Melanoma Patients: Experience, Role, and Limitations
Monica Neagu et al.
BIOMED RESEARCH INTERNATIONAL (2013)
CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma
Peter A. Prieto et al.
CLINICAL CANCER RESEARCH (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Blockade of CTLA-4 Decreases the Generation of Multifunctional Memory CD4+ T Cells In Vivo
Marion Rudolph et al.
JOURNAL OF IMMUNOLOGY (2011)
Single dose of anti-CTLA-4 enhances CD8+ T-cell memory formation, function, and maintenance
Virginia A. Pedicord et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4
Omar S. Qureshi et al.
SCIENCE (2011)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Overcoming Immunologic Tolerance to Melanoma: Targeting CTLA-4 with Ipilimumab (MDX-010)
Jeffrey Weber
ONCOLOGIST (2008)
Overcoming Immunologic Tolerance to Melanoma: Targeting CTLA-4 with Tremelimumab (CP-675,206)
Antoni Ribas
ONCOLOGIST (2008)
A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor
Jennifer C. C. Hu et al.
CLINICAL CANCER RESEARCH (2006)
Reversal of the TCR stop signal by CTLA-4
Helga Schneider et al.
SCIENCE (2006)
Tissue expression of PD-L1 mediates peripheral T cell tolerance
ME Keir et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
GM-CSF gene-transduced tumor vaccines
R Eager et al.
MOLECULAR THERAPY (2005)
Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma
R Soiffer et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Modulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS, and CTLA-4 receptors
JL Riley et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study
V Papanastassiou et al.
GENE THERAPY (2002)
Tumors and inflammatory infiltrates: Friends or foes?
C Brigati et al.
CLINICAL & EXPERIMENTAL METASTASIS (2002)
Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice
H Nishimura et al.
SCIENCE (2001)
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
GJ Freeman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial
JM Markert et al.
GENE THERAPY (2000)
Infections as a major preventable cause of human cancer
H Kuper et al.
JOURNAL OF INTERNAL MEDICINE (2000)
分享论文
